US ATTR Amyloidosis Launch Readiness

Tafamidis (Vyndaqel) holds roughly 60% of the ATTR-CM stabilizer market, but the more important fact for a pre-launch entrant is that this market is expanding rapidly, not fixed: an estimated 500,000+ US patients aged 70+ with HFpEF have undiagnosed ATTRwt-CM, against only 70,000-100,000 currently diagnosed and treated, and annual new diagnoses are running at 10,000-15,000 as Tc-PYP scintigraphy awareness grows. Acoramidis (Attruby, approved November 2024) has built 15-20% share almost entirely from newly diagnosed patients rather than tafamidis switches — confirming that capturing new diagnosis volume, not displacing the incumbent, is the correct commercial model for a new entrant.

Two structural sub-populations remain underdiagnosed and largely untapped: ATTRv (hereditary) carriers, including an estimated 100,000+ African American Val122Ile carriers (most undiagnosed, 3-4% carrier rate); and ATTR-PN (polyneuropathy), where a 4-5 year misdiagnosis delay (commonly mistaken for CIDP or diabetic neuropathy) hides 5,000-10,000 hereditary patients against only 3,000-4,000 currently diagnosed and treated. The competitive landscape is also mechanistically bifurcating (stabilizers such as tafamidis and acoramidis versus knockdown therapy such as vutrisiran, ATTR-PN approved, BLA pending for ATTR-CM), raising an unresolved commercial question a new entrant must answer: is your drug positioned as a stand-alone stabilizer, a combination partner, or a replacement mechanism?

The single most severe payer risk in this basket is ICER's tafamidis assessment: a published fair-value range of $13,000-17,000/year against a $225,000/year WAC — a 12-17x gap that has driven commercial payers to negotiate estimated net prices 40-60% below WAC. A new ATTR-CM stabilizer should expect the same scrutiny and plan pricing (likely $200,000-250,000/year WAC with comparable rebate exposure) accordingly. Pre-launch priorities: map US cardiologists ordering Tc-PYP by territory now, partner with commercial genetics labs to expand Val122Ile and TTR-gene screening in African American communities, engage community neurologists on ATTR-PN diagnostic criteria to recover the misdiagnosed backlog, and begin ICER engagement and Part D PBM contracting 18-24 months ahead of launch.

This assessment synthesises three independent research angles (competitive positioning, target-population epidemiology, and anticipated payer posture) into one integrated pre-launch view. Every figure is drawn from the named primary source in the underlying research base and cross-checked before inclusion; no figure is carried from model memory.

ATTR launch-readiness sources: IQVIA ATTR-CM diagnosis trends 2024; Pfizer tafamidis commercial data; BridgeBio investor day 2024; Alnylam ATTR prescriber analysis 2024 and HELIOS-B analysis; Ruberg FL et al., Circulation 2019; Quarta CC et al., NEJM 2015 (Val122Ile); Invitae TTR gene panel; Adams D et al., Lancet Neurol 2021 (ATTRv-PN); ICER tafamidis ATTR-CM value assessment 2021; UHC/Cigna ATTR-CM PA criteria 2024; AHA ATTR heart failure committee 2024.